Usefulness of Proton and Phosphorus MR Spectroscopic Imaging for Early Diagnosis of Parkinson's Disease

Cerebral mitochondrial dysfunction has been observed in Parkinson's disease (PD). If mitochondrial dysfunction is an early event contributing to PD development, then noninvasive techniques that detect disturbed energy metabolism in vivo might be useful tools for early diagnosis and treatment monitoring. In the present study, we tested the hypothesis that proton (1H) and phosphorus (31P) magnetic resonance spectroscopy (MRS) measures of brain metabolites are able to differentiate between individuals with early PD and healthy volunteers (HVs).

[1]  D. Turnbull,et al.  Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease , 1991, Journal of the Neurological Sciences.

[2]  Christine Klein,et al.  Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson’s Disease , 2012, Science Translational Medicine.

[3]  B D Ross,et al.  Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington's and Parkinson's diseases , 1998, Neurology.

[4]  R. Camicioli,et al.  Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia , 2004, Neuroscience Letters.

[5]  Xiangling Mao,et al.  Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T 1H MRS imaging study , 2009, NMR in biomedicine.

[6]  G. Barker,et al.  Quantitative magnetic resonance spectroscopic imaging in Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy , 2010, European journal of neurology.

[7]  Uzay E. Emir,et al.  Elevated Pontine and Putamenal GABA Levels in Mild-Moderate Parkinson Disease Detected by 7 Tesla Proton MRS , 2012, PloS one.

[8]  Carola Seifried,et al.  Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease. , 2009, Brain : a journal of neurology.

[9]  C. Clarke,et al.  Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy , 2000, European journal of neurology.

[10]  H. Yoshino,et al.  Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease , 1992, Journal of neural transmission. Parkinson's disease and dementia section.

[11]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[12]  P M Pattany,et al.  Proton MR spectroscopy of the brain in 14 patients with Parkinson disease. , 1995, AJNR. American journal of neuroradiology.

[13]  Joachim Klose,et al.  Mitochondrial Dysfunction and Oxidative Damage in parkin-deficient Mice* , 2004, Journal of Biological Chemistry.

[14]  K. Abe,et al.  Proton magnetic resonance spectroscopy of patients with parkinsonism , 2000, Brain Research Bulletin.

[15]  M. Beal.  Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. , 2009, Parkinsonism & related disorders.

[16]  Ozioma C. Okonkwo,et al.  Brain N-acetylaspartate is Reduced in Parkinson Disease With Dementia , 2008, Alzheimer disease and associated disorders.

[17]  N. Bresolin,et al.  Parkinson's Disease and Brain Mitochondrial Dysfunction: A Functional Phosphorus Magnetic Resonance Spectroscopy Study , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[19]  V J Cunningham,et al.  Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. , 2000, Brain : a journal of neurology.

[20]  M. Beal,et al.  Multinuclear Magnetic Resonance Spectroscopy for in Vivo Assessment of Mitochondrial Dysfunction in Parkinson's Disease , 2008, Annals of the New York Academy of Sciences.

[21]  S. Fahn.  Unified Parkinson's Disease Rating Scale , 1987 .

[22]  K. Abe.  Cerebral lactic acidosis correlates with neurological impairment in MELAS , 2004, Neurology.

[23]  B. Barbiroli,et al.  Phosphorus magnetic resonance spectroscopy in multiple system atrophy and Parkinson's disease , 1999, Movement Disorders.

[24]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[25]  N. Schuff,et al.  Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.

[26]  M. Hallett,et al.  Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. , 1997, Brain : a journal of neurology.

[27]  N. Hattori,et al.  Effect of Wild-type or Mutant Parkin on Oxidative Damage, Nitric Oxide, Antioxidant Defenses, and the Proteasome* , 2002, The Journal of Biological Chemistry.

[28]  Uwe Klose,et al.  Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson’s disease , 2011, European Radiology.

[29]  J. Xie,et al.  Parkinson's Disease Brain Mitochondrial Complex I Has Oxidatively Damaged Subunits and Is Functionally Impaired and Misassembled , 2006, The Journal of Neuroscience.

[30]  J H Duyn,et al.  Multisection proton MR spectroscopic imaging of the brain. , 1993, Radiology.